All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
11 warning events since 2017; the latest 2023-08-17.
From the record
CervoMed Inc.'s filings since 2017 show 11 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2021-11-05); an auditor change (8-K item 4.01, the latest 2023-08-17) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+14.9% a year over 6 filed years; profitable in 0 of 10.
From the record
CervoMed Inc.'s 6 filed years say what it did: revenue went from $570 thousand in fiscal 2011 to $4 million in fiscal 2025, up 14.9% a year; it rose in 1 of 4 years; the deepest fall was 100% from fiscal 2011 to fiscal 2022; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: CervoMed Inc.'s shareholder treatment is put at 1.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 18% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -148%: lost 148¢ per shareholder dollar. Leverage 20%: owes 20¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, CervoMed Inc. lost about 148 cents for every dollar of shareholders' money. Leverage: it owed about 20 cents per dollar of assets, and net share issuance: its share count grew 12.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 33% of 315 in its family; net margin -673.1%.
From the record
CervoMed Inc.'s standing among 315 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 33% by size; a net margin of -673.1% ranks in the bottom 34% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: CervoMed Inc.'s leadership is put at 4.5 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 45% of 415 in its family; the record of its people begins on 2023-08-11 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.2 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 45% of 273 in its family for room to expand.
From the record
CervoMed Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $8 million against no long-term debt tagged leaves 36% of its assets as net cash, top 41% of its family; cash from operations less capital spending is -585.3% of revenue (bottom 33%); research spending of 544.5% of revenue (top 27%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 32% of 306 in its family for growth drivers.
From the record
CervoMed Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew -58.9% (bottom 13%); research spending grew 153.6% a year (top 1%); capital spending grew 106.4% a year (top 8%) (its annual reports). CervoMed Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 11% of 233 in its family for expectations against reality.
From the record
CervoMed Inc.'s newest year against its own record: net income of $27 million against a prior three-year average of $8 million (bottom 8%); a net margin of a loss larger than its revenue against -98.8% before (bottom 14%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made